About the report:
-> It is an extensive progress report of industrial cancer R&D in between 2011-18.
-> All the major events which have some impact on the industry/community are included.
-> Undoubtedly, immuno-oncology are most successful so far. A detailed report is provided.
->The financial details are also included (validated by both primary and secondary market research) along with mention of the promising companies/startups.
-> Special inclusion of the checkpoint inhibitors.
-> Significant drugs in clinical trials are also included.
-> All the significant approved therapies (both new drugs and label expansions) are included.
-> All the approved therapies are also segregated by their major mechanism of action.
-> Finally, five newer tools/technologies are included with their industrial progress in detail.
-> An update of the article will be provided by the end of this year at no price!
# of Pages: 28 (Preview-available, see top-right corner)
Targetted audience: Industry & Academic Researchers, Healthcare Investors, Oncology/Biotech/Pharma Startups, Master's & Ph.D. students
Medgenera is a leading global healthcare news and publishing company. It is world’s first 100% advertisement free healthcare industry media led by a student entrepreneur. As a reader’s only platform the source of revenue is the contribution from the readers. Visit https://medgenera.com/ to know more
Please write to email@example.com for any question/assistance.
Pay what you want: